[
  {
    "ts": null,
    "headline": "Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio",
    "summary": "Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.",
    "url": "https://finnhub.io/api/news?id=33bd318ddd34b3694a95211918aaf7cb8fe53e45cc54d53475855fe34da27d53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742587997,
      "headline": "Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio",
      "id": 133325245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.",
      "url": "https://finnhub.io/api/news?id=33bd318ddd34b3694a95211918aaf7cb8fe53e45cc54d53475855fe34da27d53"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug",
    "summary": "Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.",
    "url": "https://finnhub.io/api/news?id=9b8ecdfa31a92c1bb963fa73a5e942c442540440844614d6e49f1061351cd1fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742580248,
      "headline": "Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug",
      "id": 133325246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.",
      "url": "https://finnhub.io/api/news?id=9b8ecdfa31a92c1bb963fa73a5e942c442540440844614d6e49f1061351cd1fc"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster",
    "summary": "Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an analysis of ALNY stock now.",
    "url": "https://finnhub.io/api/news?id=7b70aec7ea0443f41652733d6a52f993caea155d1cdad269f15103f5fe2cc6b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742578656,
      "headline": "Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster",
      "id": 133310859,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165310987/image_2165310987.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an analysis of ALNY stock now.",
      "url": "https://finnhub.io/api/news?id=7b70aec7ea0443f41652733d6a52f993caea155d1cdad269f15103f5fe2cc6b5"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Stock Jumps After the FDA Approves Its Heart Drug",
    "summary": "Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition.  The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease.  Alnylam has long been a favorite among biotech investors, but the company hasn’t yet shown it can transition from being a R&D innovator to a sustainable business.",
    "url": "https://finnhub.io/api/news?id=cb358b19dab6d017056033fc09aec0881dd8dff66c1782fe97567c545caf5688",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742577705,
      "headline": "Alnylam Stock Jumps After the FDA Approves Its Heart Drug",
      "id": 133325248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition.  The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease.  Alnylam has long been a favorite among biotech investors, but the company hasn’t yet shown it can transition from being a R&D innovator to a sustainable business.",
      "url": "https://finnhub.io/api/news?id=cb358b19dab6d017056033fc09aec0881dd8dff66c1782fe97567c545caf5688"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals",
    "summary": "Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.",
    "url": "https://finnhub.io/api/news?id=fb509bcc99311a52bf6d0e75ff756996ad6a6fc3dffd19d1e285b17504cf5f01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742574360,
      "headline": "Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals",
      "id": 133325250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.",
      "url": "https://finnhub.io/api/news?id=fb509bcc99311a52bf6d0e75ff756996ad6a6fc3dffd19d1e285b17504cf5f01"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Heart Drug Approval Sets Up Challenge With Pfizer",
    "summary": "(Bloomberg) -- Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech — if it can beat out stiff competition from the likes of Pfizer Inc.Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoChicago Transit Faces ‘Doomsday Scenario,’ Regional Agency SaysLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsDespite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleAmtrak",
    "url": "https://finnhub.io/api/news?id=c5cb67c0dc747af1324d255d352b4d1394f56647422d2a822e28497c57a75903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742565940,
      "headline": "Alnylam Heart Drug Approval Sets Up Challenge With Pfizer",
      "id": 133325252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech — if it can beat out stiff competition from the likes of Pfizer Inc.Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoChicago Transit Faces ‘Doomsday Scenario,’ Regional Agency SaysLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsDespite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleAmtrak",
      "url": "https://finnhub.io/api/news?id=c5cb67c0dc747af1324d255d352b4d1394f56647422d2a822e28497c57a75903"
    }
  },
  {
    "ts": null,
    "headline": "Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy",
    "summary": "Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I am upgrading BEAM.",
    "url": "https://finnhub.io/api/news?id=7c70894f08e5837301f73fda59cdf2c82427429322b85a54b41d03ba7f981381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742562824,
      "headline": "Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy",
      "id": 133307324,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316503044/image_1316503044.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I am upgrading BEAM.",
      "url": "https://finnhub.io/api/news?id=7c70894f08e5837301f73fda59cdf2c82427429322b85a54b41d03ba7f981381"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca deepens China investment; Editas loses CFO to Dyne",
    "summary": "The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.",
    "url": "https://finnhub.io/api/news?id=f486532ada742e61b2d5f300defe46053b2af5ac9e4a91ecf301108f6377e8ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742559300,
      "headline": "AstraZeneca deepens China investment; Editas loses CFO to Dyne",
      "id": 133325254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.",
      "url": "https://finnhub.io/api/news?id=f486532ada742e61b2d5f300defe46053b2af5ac9e4a91ecf301108f6377e8ae"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam shares rise on expanded heart drug approval",
    "summary": "Alnylam Pharmaceuticals'shares rose about 7% before the bell on Friday following U.S.approval for its drug for a rare and deadly heart disease,securing an entry into a market dominated by...",
    "url": "https://finnhub.io/api/news?id=a94e603d1b7733379b8bafdf69afb3e1a88f68ab194065b7f0525baf221de6f0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742542360,
      "headline": "Alnylam shares rise on expanded heart drug approval",
      "id": 133297512,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Alnylam Pharmaceuticals'shares rose about 7% before the bell on Friday following U.S.approval for its drug for a rare and deadly heart disease,securing an entry into a market dominated by...",
      "url": "https://finnhub.io/api/news?id=a94e603d1b7733379b8bafdf69afb3e1a88f68ab194065b7f0525baf221de6f0"
    }
  },
  {
    "ts": null,
    "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
    "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
    "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742541707,
      "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
      "id": 133297533,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
      "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    }
  },
  {
    "ts": null,
    "headline": "Gene therapy loses luster as investors eye quicker returns from weight-loss drugs",
    "summary": "Gene therapy, with its offer of apossible cure for rare diseases like sickle cell, is losingearly investors to higher-reward sectors like obesity andcancer, as sales for some of the new treatments...",
    "url": "https://finnhub.io/api/news?id=bde24a858bec7a836198fe12a7bf204ba33b65997eb2537cf9c6b0d51e800efb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742536800,
      "headline": "Gene therapy loses luster as investors eye quicker returns from weight-loss drugs",
      "id": 133296946,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Gene therapy, with its offer of apossible cure for rare diseases like sickle cell, is losingearly investors to higher-reward sectors like obesity andcancer, as sales for some of the new treatments...",
      "url": "https://finnhub.io/api/news?id=bde24a858bec7a836198fe12a7bf204ba33b65997eb2537cf9c6b0d51e800efb"
    }
  }
]